Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development-Reference-Cited by-同舟云学术

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

Published:2014-01-07 Issue:2 Volume:5 Page:124-127
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Zhang Zhuming¹,Chu Xin-Jie¹,Liu Jin-Jun¹,Ding Qingjie¹,Zhang Jing¹,Bartkovitz David¹,Jiang Nan¹,Karnachi Prabha¹,So Sung-Sau¹,Tovar Christian¹,Filipovic Zoran M.¹,Higgins Brian¹,Glenn Kelli¹,Packman Kathryn¹,Vassilev Lyubomir¹,Graves Bradford¹

Affiliation:

1. Discovery Chemistry, ‡Discovery Technologies, §Discovery Oncology, and ∥Non-Clinical Development, Roche Pharma Research, Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/ml400359z

Reference21 articles.

1. The p53 pathway: positive and negative feedback loops

2. The p53–Mdm2 module and the ubiquitin system

3. p53, the Cellular Gatekeeper for Growth and Division

4. Surfing the p53 network

5. p53 and Human Cancer: The First Ten Thousand Mutations

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Studying protein–protein interactions: Latest and most popular approaches;Journal of Structural Biology;2024-12

2. MDM2: current research status and prospects of tumor treatment;Cancer Cell International;2024-05-13

3. Expanding the ligand spaces for E3 ligases for the design of protein degraders;Bioorganic & Medicinal Chemistry;2024-05

4. Activation of p53 signaling and regression of breast and prostate carcinoma cells by spirooxindole-benzimidazole small molecules;Frontiers in Pharmacology;2024-04-08

5. Medicinal applications of spirooxindole and its derivatives;Spirooxindole;2024